steroid 5 alpha-reductase 3
آخر تحديث 24 Sept 2021
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
The SRD5A3 gene provides instructions for making an enzyme called steroid 5-alpha reductase 3. This enzyme performs a chemical reaction that converts a compound called polyprenol into another compound called dolichol. Subsequently, another enzyme converts dolichol to dolichol phosphate. The production of dolichol phosphate is critical for a process called glycosylation, by which small chains of sugar molecules (oligosaccharides) are attached to proteins. Glycosylation changes proteins in ways that are important for their functions.
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
The SRD5A3 gene provides instructions for making an enzyme called steroid 5-alpha reductase 3. This enzyme performs a chemical reaction that converts a compound called polyprenol into another compound called dolichol. Subsequently, another enzyme converts dolichol to dolichol phosphate. The production of dolichol phosphate is critical for a process called glycosylation, by which small chains of sugar molecules (oligosaccharides) are attached to proteins. Glycosylation changes proteins in ways that are important for their functions.
Dolichol phosphate is integral for the formation of the sugar chains that are attached to proteins during glycosylation. Individual sugars are added to dolichol phosphate to build the oligosaccharide chain. Once the chain is formed, it is transferred from dolichol phosphate to a specific site on the protein that needs to be glycosylated.
Conditions referring to this gene or chromosome
Other names
FLJ13352
SRD5A2L
SRD5A2L1
Related patient information and medicines

Patient information leaflet
تضخم البروستاتا
See the separate leaflets called. There are two groups of medicines that may help: Alpha-blockers. 5-alpha reductase inhibitors. Alpha-blocker medicines Alpha-blockers. These medicines work by relaxing the sm... This can improve the flow of urine. 5-alpha reductase inhibitor medicines. These are alternatives to alpha-blockers. These work by.

Patient information leaflet
مشاكل البروستاتا
This leaflet will... There are various treatments for the symptoms of BPH, including drugs such as alfuzosin/doxazosin (alpha-blockers), dutasteride/finasteride (5-alpha reductase inhibitors), oxybutinin/tolterodine/fesoterodine/darifenacin/solifenacin/trospium (antimuscarinics), mirabegron (for overactive bladder) and desmopressin (for frequent.

Patient information leaflet
دم في السائل المنوي
Haematospermia means there is blood in the semen. The haematospermia itself does not need any treatment. Medicines If you have persistent haematospermia without an identified cause then a type of medicine called a 5-alpha reductase inhibitor مثل finasteride Finasteride for prostate gland enlargement or dutasteride Dutasteride for prostate.

Patient information leaflet
مرض كرون
Crohn's disease is a lifelong condition with flare-ups from time to time. If symp... A course of steroids (corticosteroids) Steroid medicines Oral الستيرويدات work by reducing inflammation and are usually used first-line for those who are newly diagnosed or who have no more than one flare-up per year. The two commonly used steroids for Crohn's.

Patient information leaflet
التهاب المفاصل الصدفي
Surgery is sometimes needed if a joint or tendon becomes badly damaged. What is psoriatic arthritis. It probably occurs because the tissue which covers tendons is similar to the synovium around the joints. A commo... Codeine Codeine for pain relief is another painkiller that is sometimes used. الستيرويدات أن حقن من steroid Steroid injections.

Patient information leaflet
التهاب الفقار المقسط
The type of inflammation in AS ca... Ankylosing spondylitis is an auto-immune disease. It is not known exactly why ankylosing spondylitis occurs but there is a genetic predisposition. 6 out of 100 people who have a particular gene variant called HLA-B27 have ankylosing spondylitis whereas it is thought that it affects fewer than 1 in 100 people.
قراءة إضافية ومراجع
- steroid 5 alpha-reductase 3; MedlinePlus, National Library of Medicine.
- Ben Ayed I, Ouarda W, Frikha F, Kammoun F, Souissi A, Ben Said M, Bouzid A, Elloumi I, Hamdani TM, Gharbi N, Baklouti N, Guirat M, Mejdoub F, Kharrat N, Boujelbene I, Abdelhedi F, Belguith N, Keskes L, Gibriel AA, Kamoun H, Triki C, Alimi AM, Masmoudi S. SRD5A3-CDG: 3D structure modeling, clinical spectrum, and computer-based dysmorphic facial recognition. Am J Med Genet A. 2021 Apr;185(4):1081-1090. doi: 10.1002/ajmg.a.62065. Epub 2021 Jan 6.
- Jaeken J, Lefeber DJ, Matthijs G. SRD5A3 defective congenital disorder of glycosylation: clinical utility gene card. Eur J Hum Genet. 2020 Sep;28(9):1297-1300. doi: 10.1038/s41431-020-0647-3. Epub 2020 May 18. No abstract available.
- Kousal B, Honzik T, Hansikova H, Ondruskova N, Cechova A, Tesarova M, Stranecky V, Meliska M, Michaelides M, Liskova P. Review of SRD5A3 Disease-Causing Sequence Variants and Ocular Findings in Steroid 5alpha-Reductase Type 3 Congenital Disorder of Glycosylation, and a Detailed New Case. Folia Biol (Praha). 2019;65(3):134-141. doi: 10.14712/fb2019065030134.
- Morava E, Wevers RA, Cantagrel V, Hoefsloot LH, Al-Gazali L, Schoots J, van Rooij A, Huijben K, van Ravenswaaij-Arts CM, Jongmans MC, Sykut-Cegielska J, Hoffmann GF, Bluemel P, Adamowicz M, van Reeuwijk J, Ng BG, Bergman JE, van Bokhoven H, Korner C, Babovic-Vuksanovic D, Willemsen MA, Gleeson JG, Lehle L, de Brouwer AP, Lefeber DJ. A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism. Brain. 2010 Nov;133(11):3210-20. doi: 10.1093/brain/awq261. Epub 2010 Sep 17.
- Taylor RL, Arno G, Poulter JA, Khan KN, Morarji J, Hull S, Pontikos N, Rueda Martin A, Smith KR, Ali M, Toomes C, McKibbin M, Clayton-Smith J, Grunewald S, Michaelides M, Moore AT, Hardcastle AJ, Inglehearn CF, Webster AR, Black GC; UK Inherited Retinal Disease Consortium and the 100,000 Genomes Project. Association of Steroid 5alpha-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy. JAMA Ophthalmol. 2017 Apr 1;135(4):339-347. doi: 10.1001/jamaophthalmol.2017.0046.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
24 Sept 2021 | أحدث إصدار
1 Sept 2021 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

